AB Science (XPAR:AB) Short Interest


XPAR:AB AB Science XPAR:AB
59 GF Score
Price €0.86
GF Value €1.47
Valuation Possible Value Trap
! 11 Warning Signs
View Full Analysis

What is AB Science Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:AB vs ZTS, UTHR, VTRS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AB Science Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AB Science's Short Interest distribution charts can be found below:

* The bar in red indicates where AB Science's Short Interest falls into.


XPAR:AB
59GF Score
AB Science XPAR:AB
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (XPAR:AB) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of €0.86 is trading 41.6% below its estimated GF Value™ of €1.47. GuruFocus considers AB Science to be Possible Value Trap.

Key valuation signals for XPAR:AB:

  • Short Interest:
  • GF Value™: €1.47 vs. price of €0.86 (41.6% below fair value)
  • GF Score™: 59/100 with 11 warning signs

No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges ABSCF:USA0Q77:UKA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
59GF Score

Get the complete analysis for XPAR:AB

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price
€1.47
GF Value